Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pulmonary pharmacology and therapeutics

  • Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
    Lavanya Raman, Iain Stewart, Shaney L. Barratt, Felix Chua, Nazia Chaudhuri, Anjali Crawshaw, Michael Gibbons, Charlotte Hogben, Rachel Hoyles, Vasilis Kouranos, Jennifer Martinovic, Sarah Mulholland, Katherine J. Myall, Marium Naqvi, Elisabetta A. Renzoni, Peter Saunders, Matthew Steward, Dharmic Suresh, Muhunthan Thillai, Athol U. Wells, Alex West, Jane A. Mitchell, Peter M. George
    ERJ Open Research Mar 2023, 9 (2) 00423-2022; DOI: 10.1183/23120541.00423-2022
  • AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study
    Hunter Gillies, Ralph Niven, Benjamin T. Dake, Murali M. Chakinala, Jeremy P. Feldman, Nicholas S. Hill, Marius M. Hoeper, Marc Humbert, Vallerie V. McLaughlin, Martin Kankam
    ERJ Open Research Mar 2023, 9 (2) 00433-2022; DOI: 10.1183/23120541.00433-2022
  • Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
    Lucia De Prado Gomez, Ian Pavord, William Busse, Christopher E. Brightling, Michael E. Wechsler, Klaus F. Rabe, Mei Zhang, Jun Xing, Juby A. Jacob-Nara, Paul J. Rowe
    ERJ Open Research Mar 2023, 9 (2) 00417-2022; DOI: 10.1183/23120541.00417-2022
  • Triple therapy in COPD: understanding the data
    Samy Suissa
    ERJ Open Research Jan 2023, 9 (1) 00615-2022; DOI: 10.1183/23120541.00615-2022
  • Use of inhaled ipratropium bromide to improve exercise-induced laryngeal obstruction cannot be recommended
    Praveen Muralitharan, Petter Carlsen, Magnus Hilland, Irisz Delestre-Levai, Maria Vollsæter, Karl Ove Hufthammer, Mette Engan, Ola Drange Røksund, Thomas Halvorsen, Hege H. Clemm
    ERJ Open Research Jan 2023, 9 (1) 00308-2022; DOI: 10.1183/23120541.00308-2022
  • Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
    Yuriko Ishida, Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takashi Ogura
    ERJ Open Research Oct 2022, 8 (4) 00337-2022; DOI: 10.1183/23120541.00337-2022
  • Interferon-γ release assay screening in biologics: safe and reliable, but not perfect
    John Cafferkey, Yorissa Padayachee, Sophia Kostich, Kartik Kumar, Paul Jewell, Mikin Patel, Aneeka Chavda, Alison Cox, Mirae Park, Georgina Russell, Meg Coleman, Laura Martin, Onn Min Kon
    ERJ Open Research Oct 2022, 8 (4) 00193-2022; DOI: 10.1183/23120541.00193-2022
  • AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
    Shahid Siddiqui, Claus Bachert, Adam M. Chaker, Joseph K. Han, Peter W. Hellings, Anju T. Peters, Enrico Heffler, Siddhesh Kamat, Haixin Zhang, Scott Nash, Asif H. Khan, Lucia De Prado Gomez, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz
    ERJ Open Research Oct 2022, 8 (4) 00085-2022; DOI: 10.1183/23120541.00085-2022
  • Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
    Hirokazu Urushiyama, Taisuke Jo, Wakae Hasegawa, Akira Yokoyama, Takahiro Ando, Yukiyo Sakamoto, Ryosuke Kumazawa, Kazuaki Uda, Nobuaki Michihata, Nobuyasu Awano, Matsui Hiroki, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase
    ERJ Open Research Oct 2022, 8 (4) 00209-2022; DOI: 10.1183/23120541.00209-2022
  • Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
    Danya Muilwijk, Domenique D. Zomer-van Ommen, Vincent A.M. Gulmans, Marinus J.C. Eijkemans, Cornelis K. van der Ent, Dutch Cystic Fibrosis Registry (NCFR) Steering Group: , J. Altenburg, S.W.J. Terheggen-Lagro, H.G.M. Heijerman, K.M. de Winter-de Groot, M. Bakker, R.A.S. Hoek, H.M. Janssens, R. van der Meer, M. Nuijsink, H. van der Vaart, G.H. Koppelman, L.H. Conemans, M.A.G.E. Bannier, J.J. Noordhoek
    ERJ Open Research Oct 2022, 8 (4) 00204-2022; DOI: 10.1183/23120541.00204-2022

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 14
  • Acute lung injury and critical care (47)
  • Asthma and allergy (226)
  • CF and non-CF bronchiectasis (138)
  • COPD and smoking (344)
  • Epidemiology, occupational and environmental lung disease (59)
  • Genetics (29)
  • Interstitial and orphan lung disease (176)
  • Lung biology and experimental studies (84)
  • Lung cancer (77)
  • Lung imaging (59)
  • Lung structure and function (114)
  • Mechanisms of lung disease (4)
  • Paediatric pulmonology (111)
  • Pulmonary pharmacology and therapeutics (139)
  • Pulmonary vascular disease (93)
  • Respiratory clinical practice (94)
  • Respiratory infections and tuberculosis (353)
  • Sleep medicine (57)
  • Most Read
  • Twitter
Loading
  • Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?
  • IQOS exposure impairs human airway cell homeostasis: direct comparison with traditional cigarette and e-cigarette
  • A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study
  • Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study
  • ERS International Congress 2020: highlights from the General Pneumology Assembly
More...

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society